NCT04172025 Development of a Swiss Surveillance Database for Molecular Epidemiology of Hypervirulent and Multi-drug Resistant Pathogens
| NCT ID | NCT04172025 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Multiresistant Bacterial Pathogens |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2019-09-30 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2019-09-30 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypervirulent and multidrug-resistant infections are associated with significant health care costs, substantial morbidity and mortality. Therefore, the rapid recognition of outbreaks and transmissions with hypervirulent and multi-drug resistant pathogen is a key priority for infection control and public health.The main goal is to implement a shared database, connecting human and veterinary microbiology laboratories, which would allow near real-time molecular epidemiology with high spatiotemporal resolution of bacterial pathogens such as transmission and outbreak surveillance between different compartments including humans, animals and the environment in Switzerland. Investigator aims to analyze already collected encoded retrospective datasets of various pathogens by combining epidemiological data and whole genome sequences from pathogens.
Eligibility Criteria
Inclusion Criteria: * All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data * Pathogens included into analysis are: Multidrug-resistant bacteria include: methicillin resistant Staphylococcus aureus (MRSA), Carbapenemase- and/or extended spectrum betalactamase (ESBL)-producing Enterobacteriaceae and non-fermenting bacteria including Pseudomonas aeruginosa and Acinetobacter baumannii, Vancomycin resistant Enterococcus faecium, and others; virulent bacteria include: Neisseria meningitidis, Neisseria gonorrhoeae, Mycobacterium tuberculosis, Campylobacter spp., Salmonella spp., Legionella pneumophila, Listeria monocytogenes, and Streptococcus pneumoniae, and others; Viruses include: Influenza viruses, Measles virus, Enterovirus E68, Respiratory Syncytial Virus and others. Exclusion Criteria: * Decline to sign a general consent or any other declining statement against using data for research purposes.
Contact & Investigator
Hans Hirsch, Prof. Dr.
PRINCIPAL INVESTIGATOR
Biozentrum, University of Basel
Frequently Asked Questions
Who can join the NCT04172025 clinical trial?
This trial is open to participants of all sexes, studying Multiresistant Bacterial Pathogens. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04172025 currently recruiting?
Yes, NCT04172025 is actively recruiting participants. Contact the research team at hans.hirsch@unibas.ch for enrollment information.
Where is the NCT04172025 trial being conducted?
This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Geneva, Switzerland, Lausanne, Switzerland and 1 additional location.
Who is sponsoring the NCT04172025 clinical trial?
NCT04172025 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Hans Hirsch, Prof. Dr. at Biozentrum, University of Basel. The trial plans to enroll 10,000 participants.